- Lobbying
- Lobbying by Boehringer Ingelheim Pharmaceuticals, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Stuart Chapman | Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee Chief of Staff, Rep. Carolyn McCarthy; Chief of Staff, Rep. Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary,Rep. Barbara Lee |
Sheryl Cohen | Chief of Staff, Senator Christopher Dodd; Political Director, Senator Christopher Dodd; Finance Director, Senator Joe Lieberman |
Chris Israel | U.S. Coordinator for International IP Enforcement; Deputy Chief of Staff, Department of Commerce; Deputy Assistant Secretary for Tech Policy, Department of Commerce. |
Stephen Pinkos | Policy Director/General Counsel - House Majority Whip Kevin McCarthy; Deputy Undersecretary of Commerce for IP; Staff Director, House Judiciary Committee Policy Director/General Counsel, House Majority Whip Kevin McCarthy; Deputy Undersecretary of Commerce for IP; Staff Director, House Judiciary Committee |
Sheryl Chapman | n/a |
Caitlyn Wilson | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Termination
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Cost Sharing (Preserving Access to Medicines).
Healthcare Exchanges.
Average Sales Price.
Reimbursements.
CHIP.
Rebates for Dual Eligibles and Low-Income Subsidy Populations in Medicare Part D.
Importation.
Non-Interference.
21st Century Cures..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate